PL2803663T3 - Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne - Google Patents

Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne

Info

Publication number
PL2803663T3
PL2803663T3 PL14166121T PL14166121T PL2803663T3 PL 2803663 T3 PL2803663 T3 PL 2803663T3 PL 14166121 T PL14166121 T PL 14166121T PL 14166121 T PL14166121 T PL 14166121T PL 2803663 T3 PL2803663 T3 PL 2803663T3
Authority
PL
Poland
Prior art keywords
protein tyrosine
human protein
pharmaceutical use
tyrosine phosphatase
phosphatase inhibitors
Prior art date
Application number
PL14166121T
Other languages
English (en)
Inventor
Jeffrey Lyle Gray
Cynthia Monesa Clark
Kande Amarasinghe
Mathew Brian Maier
Ryan Nichols
Original Assignee
Aerpio Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38704718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2803663(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aerpio Therapeutics, Inc. filed Critical Aerpio Therapeutics, Inc.
Publication of PL2803663T3 publication Critical patent/PL2803663T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14166121T 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne PL2803663T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81682506P 2006-06-27 2006-06-27
EP07809909.0A EP2041129B1 (en) 2006-06-27 2007-06-27 Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use
EP14166121.5A EP2803663B1 (en) 2006-06-27 2007-06-27 Human protein tyrosine phosphatase inhibitors and their pharmaceutical use

Publications (1)

Publication Number Publication Date
PL2803663T3 true PL2803663T3 (pl) 2018-05-30

Family

ID=38704718

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14166121T PL2803663T3 (pl) 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne
PL07809909T PL2041129T3 (pl) 2006-06-27 2007-06-27 Czynniki hamujące ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07809909T PL2041129T3 (pl) 2006-06-27 2007-06-27 Czynniki hamujące ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne

Country Status (23)

Country Link
US (3) US7589212B2 (pl)
EP (3) EP2041129B1 (pl)
JP (1) JP5201740B2 (pl)
KR (1) KR101157844B1 (pl)
CN (1) CN101506204B (pl)
AU (1) AU2007265455B2 (pl)
BR (1) BRPI0713349A2 (pl)
CA (1) CA2656915C (pl)
CO (1) CO6150143A2 (pl)
CY (1) CY1115588T1 (pl)
DK (2) DK2041129T3 (pl)
ES (2) ES2510674T3 (pl)
HK (1) HK1203960A1 (pl)
IL (1) IL196130A (pl)
MX (1) MX2009000290A (pl)
NZ (1) NZ574405A (pl)
PL (2) PL2803663T3 (pl)
PT (2) PT2041129E (pl)
RU (1) RU2430101C2 (pl)
SI (1) SI2041129T1 (pl)
TR (1) TR201802280T4 (pl)
WO (1) WO2008002571A2 (pl)
ZA (1) ZA200900558B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
AU2014202211B2 (en) * 2009-01-12 2016-06-02 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
JP5558489B2 (ja) * 2009-01-12 2014-07-23 アケビア セラピューティクス インコーポレイテッド 血管漏出症候群を治療する方法
EP3556367A1 (en) 2009-07-06 2019-10-23 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in the treatment of cancer or metastasis
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011057121A1 (en) 2009-11-06 2011-05-12 Akebia Therapeutics Inc. Compositions and methods for treating colitis
US20120129847A1 (en) * 2010-10-07 2012-05-24 Kevin Gene Peters Compositions and methods for treating ocular edema, neovascularization and related diseases
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
RU2507597C2 (ru) * 2012-05-23 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы никорандилом
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
GB2549865B (en) 2013-03-15 2018-01-17 Aerpio Therapeutics Inc Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases
RU2526466C1 (ru) * 2013-04-04 2014-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Средство для стимуляции васкуляризации сердечной мышцы при постинфарктном ее ремоделировании в эксперименте
EP3107542B1 (en) 2014-02-19 2019-05-01 Aerpio Therapeutics, Inc. Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
CN106456614A (zh) * 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
US10900319B2 (en) 2017-12-14 2021-01-26 Exacta-Frac Energy Services, Inc. Cased bore straddle packer
JP7695187B2 (ja) 2018-09-24 2025-06-18 アイポイント ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
EP4051267A4 (en) 2019-10-29 2023-12-06 EyePoint Pharmaceuticals, Inc. TIE-2 SMALL MOLECULE ACTIVATORS
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673641A (en) * 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2298325T3 (es) * 1992-03-13 2008-05-16 Biomerieux B.V. Peptidos y secuencias de acido nucleico relacionadas con el virus epstein barr.
AU4373993A (en) * 1992-05-14 1993-12-13 Ohio State University Research Foundation, The Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
JPH106346A (ja) * 1996-06-19 1998-01-13 Takemoto Oil & Fat Co Ltd プラスチック成形型の製造方法及びプラスチック成形型
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
AU5062500A (en) 1999-04-26 2000-11-10 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
AU5147700A (en) * 1999-05-19 2000-12-05 Amgen, Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
IL148243A0 (en) 1999-08-27 2002-09-12 Sugen Inc Trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and pharmaceutical compositions containing the same
US6589758B1 (en) * 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
CN1571796A (zh) 2000-09-27 2005-01-26 宝洁公司 黑皮素受体配体
AR038703A1 (es) * 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
WO2003082263A1 (en) * 2002-03-29 2003-10-09 Ontogen Corporation Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20050154011A1 (en) * 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
KR20060073626A (ko) * 2003-09-17 2006-06-28 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 고휘도 방전 램프
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
EP3556367A1 (en) 2009-07-06 2019-10-23 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in the treatment of cancer or metastasis

Also Published As

Publication number Publication date
RU2009102537A (ru) 2010-08-10
HK1203960A1 (en) 2015-11-06
EP2803663A1 (en) 2014-11-19
WO2008002571A3 (en) 2008-02-14
KR101157844B1 (ko) 2012-06-22
MX2009000290A (es) 2009-03-16
DK2803663T3 (en) 2018-03-05
PT2803663T (pt) 2018-02-28
US8188125B2 (en) 2012-05-29
CN101506204A (zh) 2009-08-12
AU2007265455B2 (en) 2011-11-10
KR20090024296A (ko) 2009-03-06
JP2009542660A (ja) 2009-12-03
CO6150143A2 (es) 2010-04-20
ES2660571T3 (es) 2018-03-23
PT2041129E (pt) 2014-10-08
SI2041129T1 (sl) 2014-11-28
CN101506204B (zh) 2012-05-30
AU2007265455A1 (en) 2008-01-03
US8338615B2 (en) 2012-12-25
CA2656915A1 (en) 2008-01-03
JP5201740B2 (ja) 2013-06-05
NZ574405A (en) 2012-01-12
WO2008002571B1 (en) 2008-04-17
CY1115588T1 (el) 2017-01-04
IL196130A0 (en) 2009-09-22
WO2008002571A2 (en) 2008-01-03
IL196130A (en) 2014-04-30
US20070299116A1 (en) 2007-12-27
US20120077853A1 (en) 2012-03-29
EP2803663B1 (en) 2017-11-29
TR201802280T4 (tr) 2018-03-21
AU2007265455A2 (en) 2009-05-21
US7589212B2 (en) 2009-09-15
DK2041129T3 (da) 2014-10-13
BRPI0713349A2 (pt) 2012-03-06
EP2041129A2 (en) 2009-04-01
HK1129388A1 (en) 2009-11-27
ZA200900558B (en) 2012-04-24
PL2041129T3 (pl) 2014-11-28
RU2430101C2 (ru) 2011-09-27
CA2656915C (en) 2012-08-07
US20090227639A1 (en) 2009-09-10
EP3287455A1 (en) 2018-02-28
EP2041129B1 (en) 2014-09-03
ES2510674T3 (es) 2014-10-21

Similar Documents

Publication Publication Date Title
PL2803663T3 (pl) Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne
PL2592072T3 (pl) Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie
IL196129A0 (en) Human protein tyrosine phosphatase inhibitors and methods of use
IL193473A0 (en) Amide derivatives and their application for the treatment of g protein related diseases
IL184735A0 (en) Pharmaceutical formulations and methods of use
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
IL195491A (en) Pharmaceutical compositions of tmc278 and processes for their preparation
EP2021455A4 (en) SYSTEM FOR PREPARING CYTOBLOCS AND METHODS OF USE THEREOF
IL206690A0 (en) Protein kinase inhibitors and their use in the preparation of medicaments
IL207415A0 (en) Protein kinase inhibitors and use thereof
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
GB0722996D0 (en) Depsipeptides and their therapeutic use
IL193700A0 (en) Medicaments and proteins
GB0516069D0 (en) Pharmaceutical and use thereof
EP1922086A4 (en) TARGETED PROTEIN KINASE C HEMMER AND ITS USES
EP2045245A4 (en) IRREVERSIBLE TYROSINE KYNASES INHIBITORS AND METHODS OF PREPARATION AND USES THEREOF
ZA200900492B (en) Human protein tyrosine phosphatase inhibitors and methods of use
BRPI0719997A2 (pt) Uso de epotilonas no tratamento de osteoporose e doenças relacionadas
EP1885381A4 (en) PHARMACEUTICAL USE OF GRAPTOPETALUM AND RELATED PLANTS
GB0614365D0 (en) Pharmaceutical compositions and their use
ZA200904382B (en) Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-retaled diseases
TH0601002495A (th) สารผสมตามสูตรทางเภสัชกรรมและวิธีการของการบำบัดรักษาซึ่งใช้สิ่งดังกล่าว
IL198079A0 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
HK1134300A (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases